New-generation cytopathological staining platform could be a reliable diagnostic tool to help determine whether and when to perform a prostate biopsy. Called CellDetect, trials for accurate cancer detection, demonstrated successful detection of prostate cancer cells in urine samples with 91.3% sensitivity and 75% specificity. Current screening tests for prostate cancer deliver a high rate of false positive results (as low as 25% specificity), leading to unnecessary invasive diagnostic tests such as biopsies. CellDetect has proven effective in diagnosing cervical and bladder cancer and it is expected that the technology can be implemented for use in additional cancer detection indications. For the prostate cancer indication, a blinded study is planned to confirm these exciting findings.